menu
    • menu

    Company profile for Galmed Pharmaceuticals

    NEW Drugs in Dev: 3
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a clinical-stage biopharmaceutical company focused on the development of Aramchol™, liver-targeted stearoyl-coenzyme A desaturase‑1 (“SCD1ˮ) modulator, a first in class, novel, once-daily, oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis). We believe that our product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, whi...
    We are a clinical-stage biopharmaceutical company focused on the development of Aramchol™, liver-targeted stearoyl-coenzyme A desaturase‑1 (“SCD1ˮ) modulator, a first in class, novel, once-daily, oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis). We believe that our product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that constitutes a large unmet medical need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Galmed PharmaceuticalsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    16 Tiomkin Street Tel Aviv, 6578317 Israel
    Telephone
    Telephone
    +972.3.693.8448
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://galmedpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    IMCAS Asia

    IMCAS Asia

    Not Confirmed

    envelop Contact Supplier

    IMCAS Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galmed to Acquire Colospan for $6B GI Market Opportunity
    Galmed to Acquire Colospan for $6B GI Market Opportunity

    08 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-acquire-colospan-to-create-a-gi-focused-platform-targeting-a-6-billion-market-302793948.html

    PR NEWSWIRE
    08 Jun 2026
    Share Share
    Tissue Dynamics, Galmed Uncover Metabolic Pathway in Fibrosis
    Tissue Dynamics, Galmed Uncover Metabolic Pathway in Fibrosis

    02 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tissue-dynamics-and-galmed-unveil-unknown-metabolic-pathway-for-cardiac-fibrosis-and-heart-failure-which-supports-the-development-of-aramchol-for-cardiac-fibrosis-302788311.html

    PR NEWSWIRE
    02 Jun 2026
    Share Share
    Galmed's Oral Aramchol Meglumine Boosts Bioavailability 500%
    Galmed's Oral Aramchol Meglumine Boosts Bioavailability 500%

    14 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-results-from-first-in-man-pharmacokinetics-study-of-oral-formulation-of-aramchol-meglumine-am-400mg-am-increases-bioavailability-by-500-in-comparison-to-aramchol-free-acid-aa-300mg-302772195.html

    PR NEWSWIRE
    14 May 2026
    Share Share
    Tissue Dynamics, Galmed Develop Cardiac Fibrosis Platform
    Tissue Dynamics, Galmed Develop Cardiac Fibrosis Platform

    06 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tissue-dynamics-and-galmed-pharmaceuticals-to-develop-human-centered-chronic-cardiac-fibrosis-platform-to-advance-aramchol-based-therapeutics-302763979.html

    PR NEWSWIRE
    06 May 2026
    Share Share
    Galmed Collaborates With Tel Aviv University To Assess Aramchol
    Galmed Collaborates With Tel Aviv University To Assess Aramchol

    14 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-a-collaboration-agreement-with-tel-aviv-university-to-evaluate-its-scd1-inhibitor-aramchol-as-a-targeted-therapy-for-metastatic-brain-cancers-302741560.html

    PR NEWSWIRE
    14 Apr 2026
    Share Share
    Galmed Unveils Brain-Penetrating Aramchol SCD1 Inhibitor
    Galmed Unveils Brain-Penetrating Aramchol SCD1 Inhibitor

    09 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-the-breakthrough-development-of-a-brain-penetrating-new-formulation-of-its-scd1-inhibitor-aramchol-302738096.html

    PR NEWSWIRE
    09 Apr 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search